Functional TRPV and TRPM channels in human preadipocytes.
Preadipocytes are widely used as an in vitro model to investigate proliferation, adipogenic differentiation, and lipodystrophy; however, cellular physiology and biology are not fully understood in human preadipocytes. The present study was to investigate the expression of transient receptor potential (TRP) channels in human preadipocytes and their potential roles in regulating proliferation and adipogenic differentiation using approaches of confocal microscopy, whole-cell patch voltage-clamp, reverse transcription polymerase chain reaction, Western blot, etc. We found that TRPV2, TRPV4, and TRPM7 channels were abundantly expressed in human preadipocytes. The intracellular Ca(2+) transient activated by the TRPV2 activator probenecid was reversed or prevented by ruthenium red, a TRPV2 blocker. The TRPV4 channel activator, 4α-phorbol 12-13-dicaprinate, enhanced intracellular Ca(2+) oscillations, and the effect was inhibited by the TRPV4 blocker RN-1734. TRPM7 current was recorded with dialysis of Mg(2+)-free pipette solution, which was inhibited by the TRP channel blocker 2-aminoethoxydiphenyl borate and enhanced by acidic extracellular pH. Silencing TRPV2 or TRPM7, but not TRPV4, significantly reduced cell proliferation via inhibiting cyclin D1, cyclin E, and p-ERK1/2. Interestingly, individually silencing these three channels decreased adipogenic differentiation of human preadipocytes by reducing p-Akt kinase. Our results demonstrate for the first time that functional TRPV2, TRPV4, and TRPM7 channels are abundantly expressed in human preadipocytes. TRPV2 and TRPM7, but not TRPV4, regulate cell proliferation via activating cyclin D1, cyclin E, and p-ERK1/2, while they are all involved in adipogenesis in human preadipocytes via phosphorylating Akt kinase.
Department of Medicine, Li-Ka Shing Faculty of Medicine, University of Hong Kong, Laboratory Block, FMB, 21 Sassoon Road, Pokfulam, Hong Kong, China.
Hui
H
Che
Jianbo
J
Yue
Hung-Fat
HF
Tse
Gui-Rong
GR
Li
D000200:Action Potentials; D017667:Adipocytes / Q000166:cytology / Q000378:metabolism* / Q000502:physiology; D050156:Adipogenesis; D053687:Adult Stem Cells / Q000166:cytology / Q000378:metabolism* / Q000502:physiology; D020013:Calcium Signaling; D049109:Cell Proliferation; D019938:Cyclin D1 / Q000378:metabolism; D019927:Cyclin E / Q000378:metabolism; D006801:Humans; D020935:MAP Kinase Signaling System; D010703:Phorbol Esters / Q000494:pharmacology; D011339:Probenecid / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012430:Ruthenium Red / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology; D050053:TRPM Cation Channels / Q000235:genetics / Q000378:metabolism*; D050916:TRPV Cation Channels / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*
D019927:Cyclin E; D010703:Phorbol Esters; C544743:RN 1734; D012333:RNA, Messenger; D013449:Sulfonamides; D050053:TRPM Cation Channels; D050916:TRPV Cation Channels; C400769:TRPV2 protein, human; C416986:TRPV4 protein, human; D012430:Ruthenium Red; D019938:Cyclin D1; C008876:phorbol-12,13-didecanoate; D017346:Protein Serine-Threonine Kinases; C486583:TRPM7 protein, human; D011339:Probenecid